BDBM299642 US9593110, Example 101b::US9593110, Example 101c::US9593110, Example 102b::US9593110, Example 102c::US9593110, Example 103b::US9593110, Example 103d::US9593110, Example 105::US9593110, Example 106::US9593110, Example 87b::US9593110, Example 88b::US9593110, Example 89b::US9593110, Example 90b::US9593110, Example 91b::US9593110, Example 92b::US9593110, Example 93b::US9593110, Example 94b::US9593110, Example 95b

SMILES CCOC(=O)[C@H](COS(=O)(=O)c1ccc(Br)cc1)C[C@@H](Cc1ccc(cc1)-c1cc(Cl)ccc1F)NB(C)O

InChI Key InChIKey=XUESFXPWPSYPQC-NZQKXSOJSA-N

Data  17 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 299642   

TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi:  2.20nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 101b | US9593110, Example 101c ...)
Affinity DataKi:  2.20nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent